687 related articles for article (PubMed ID: 16914571)
21. Novel blood biomarkers of human urinary bladder cancer.
Osman I; Bajorin DF; Sun TT; Zhong H; Douglas D; Scattergood J; Zheng R; Han M; Marshall KW; Liew CC
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3374-80. PubMed ID: 16740760
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer.
Wang Y; Chen W; Yang C; Wu W; Wu S; Qin X; Li X
Int J Oncol; 2012 Jul; 41(1):276-84. PubMed ID: 22576688
[TBL] [Abstract][Full Text] [Related]
23. Molecular urinary sediment analysis in patients with transitional cell bladder carcinoma.
Dal Canto M; Bartoletti R; Travaglini F; Piazzini M; Lodovichi G; Rizzo M; Selli C
Anticancer Res; 2003; 23(6D):5095-100. PubMed ID: 14981972
[TBL] [Abstract][Full Text] [Related]
24. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
25. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
26. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
27. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array.
Hoque MO; Lee J; Begum S; Yamashita K; Engles JM; Schoenberg M; Westra WH; Sidransky D
Cancer Res; 2003 Sep; 63(18):5723-6. PubMed ID: 14522891
[TBL] [Abstract][Full Text] [Related]
28. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.
Ham WS; Lee JH; Yu HS; Choi YD
Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660
[TBL] [Abstract][Full Text] [Related]
29. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
31. Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: preliminary results.
Elsamman E; Fukumori T; Ewis AA; Ali N; Kajimoto K; Shinohara Y; Ishikawa M; Takahashi M; Nishitani MA; Baba Y; Kanayama HO
Urol Oncol; 2006; 24(2):109-15. PubMed ID: 16520272
[TBL] [Abstract][Full Text] [Related]
32. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
33. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.
Eissa S; Matboli M; Essawy NO; Shehta M; Kotb YM
Biomarkers; 2015; 20(3):212-7. PubMed ID: 26161701
[TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.
Yang C; Li X; Wang Y; Zhao L; Chen W
Gene; 2012 Mar; 496(1):8-16. PubMed ID: 22285928
[TBL] [Abstract][Full Text] [Related]
35. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
36. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
37. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer.
Eissa S; Swellam M; Ali-Labib R; Mansour A; El-Malt O; Tash FM
J Urol; 2007 Sep; 178(3 Pt 1):1068-72. PubMed ID: 17644139
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetic diagnosis of de novo and recurrent bladder cancer.
Steiner G; Reinschmidt G; Müller SC
Electrophoresis; 1999 Feb; 20(2):280-2. PubMed ID: 10197434
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
Moussa O; Abol-Enein H; Bissada NK; Keane T; Ghoneim MA; Watson DK
J Urol; 2006 Jun; 175(6):2312-6. PubMed ID: 16697865
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of CA19-9 as a tumor marker in urothelial malignancy.
Chuang CK; Liao SK
Scand J Urol Nephrol; 2004; 38(5):359-65. PubMed ID: 15764245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
